|View printer-friendly version|
|October 22, 2002 4:22 p.m.|
|Teva Announces That Early Treatment of MS with Copaxone® delays Accumulation of Additional Brain Lesions|
Jerusalem, Israel, October 22, 2002 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that according to a study published in the October 2002 issue of Neurology, people living with relapsing-remitting multiple sclerosis who delay Copaxone® (glatiramer acetate) treatment for as little as nine months can accumulate additional lesions in their brain. The delay of starting therapy resulted in six new enhancing lesions per patient during the first nine study months that could have been prevented, according to the study.